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Background: Cystatin SN is a secreted protein and a cysteine proteinase inhibitor. It has been considered to be a
tumor marker for gastrointestinal tract cancer in several functional researches. However, the clinicopathological and
prognostic significance of Cystatin SN expression in esophageal squamous cell carcinoma (ESCC) has not been
elucidated.
Methods: In our study, the expression of Cystatin SN was detected in 209 surgically resected ESCC tissues and 170
peritumoral normal esophageal mucosae by immunohistochemistry. The prognostic significance of Cystatin SN
expression was analysed with Kaplan-Meier plots and the Cox proportional hazards regression models.
Results: The results showed that the immunostaining of Cystatin SN in ESCC tissues was less intense than that in
the normal control tissue (P < 0.001). Compared with patients with low tumoral Cystatin SN expression, ESCC
patients with tumors high-expression Cystatin SN exhibited increased disease-free survival (DFS) and overall survival
(OS) (P < 0.001 and P < 0.001, respectively). Furthermore, the expression level of Cystatin SN could further stratify the
ESCC patients by survival (DFS and OS) in the stage II subgroup (P < 0.001 and P < 0.001, respectively). Multivariate
analyses showed that Cystatin SN expression, N status and differentiation were independent and significant
predictors of survival.
Conclusions: We concluded that ESCC patients whose tumors express high levels of Cystatin SN have favourable
survival compared with those patients with low Cystatin SN expression. Tumoral Cystatin SN expression may be an
independent predictor of survival for patients with resectable ESCCs.
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Esophageal cancer (EC) is the fourth leading cause
of cancer-related death worldwide, and there were
approximately 482,300 new esophageal cancer cases and
406,800 EC-related deaths in 2008, with incidence
rates varying almost 16-fold throughout the world [1].
China accounts for approximately 53.6% of new cases
and 51.7% of EC-related worldwide [2]. In China,* Correspondence: wenzhsh@sysucc.org.cn
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reproduction in any medium, provided the orapproximately 90% of all esophageal cancers are squa-
mous cell carcinomas [2,3]. The best option for curing
esophageal squamous cell carcinoma (ESCC) is surgical
resection, but the delayed clinical presentation of symp-
toms (e.g., dysphagia and odynophagia) may result in the
loss of the opportunity to undergo surgery. Even with
the development of surgical techniques and better post-
operative management, the 5-year survival rate of pa-
tients after complete surgical resection only ranges from
10% to 40% [4].
Cysteine proteases are involved in tissue remodeling
during development, and they induce the migration of
cancer cells [5,6]. The expression, function and location
of many proteases are associated with tumor progressiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association between Cystatin SN expression and
clinicopathological variables in 209 ESCC patients
Variables Cases
Cystatin SN expression (%)
Low (−to+) High (++to+++) P value*




≤ 57 113 83(73.5) 30(26.5)
> 57 96 62(64.6) 24(35.4)
Gender 0.328
Male 150 107(71.3) 43(28.7)
Female 59 38(64.4) 21(35.6)
Tumor location 0.699
Upper 15 9(60.0) 6(40.0)
Middle 96 68(70.8) 28(29.2)
Lower 98 68(69.4) 30(30.6)
Differentiation 0.200
G1 56 39(69.6) 17(30.4)
G2 105 68(64.8) 37(35.2)
G3 48 38(79.2) 10(20.8)
pT status 0.133
pT1 4 1(25.0) 3(75.0)
pT2 62 42(67.7) 20(32.3)
pT3 143 102(71.3) 41(28.7)
pN status 0.176
pN0 116 76(65.5) 40(34.5)
pN1-3 93 69(74.2) 24(25.8)
pTNM status 0.183
II 133 88(66.2) 45(33.8)
III 76 57(75.0) 19(25.0)
*Chi-square test; †median age was 57 years for 209 enrolled ESCC patients.
G grade, pT pathologic tumor, pN pathologic node, pTNM
pathologic tumor-node-metastasis.
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tions on tumor cells, but efforts have shifted to the role
of cathepsins in the progression of tumor cells, with the
goal of designing a novel protease-based drug to attenu-
ate the invasive and metastatic capabilities of tumor cells
[5]. Simultaneously, recent evidence suggests that lyso-
somal cysteine proteases play an important role in ESCC
growth, invasion and metastasis [7,8].
The CST1 gene encodes a secretory peptide called
Cystatin SN, which is a cysteine proteinase inhibitor [9].
The balance between cathepsins and their cystatins has
been reported to influence various pathological pro-
cesses, including tumor invasion and metastasis [10,11].
Cystatin SN is one of the family 2 cystatins (including
cystatins C, D, S, SA, SN, M and F), which are encoded
by one subfamily of the Cystatin (CST) superfamily [12].
There have been reported that most of the family 2
Cystatins (excluding Cystatin SA) are closely associated
with tumor metastasis and invasion [6,11,13-21]. In par-
ticular, CST1 plays an important role in the regulation
of proteolysis and is highly involved in gastric tumori-
genesis though TCF-mediated proliferative signalling [6].
At the same time, CST1 was also identified as a tumor
marker for colorectal cancer [21] although this finding
lacks the support of clinicalpathological data. All previ-
ous observations have implied that Cystatin SN may
contribute to the process of carcinogenesis and tumor
progression. However, the clinicopathological and prog-
nostic significance of Cystatin SN in human ESCC has
not yet been elucidated.
Based on these considerations, in our study, we
analysed Cystatin SN protein expression in surgically
resected ESCCs from a large patient cohort. Further-
more, we have discussed the clinicopathological and
prognostic value of Cystatin SN expression in ESCCs.
Methods
Between October 2000 and April 2007, 240 primary
ESCC patients underwent complete surgical resection
(R0) at the Sun Yat-sen University Cancer Center
were eligible for our study. After exclusion of the
noninformative samples (e.g., unrepresentative and
lost samples), a total of 209 ESCC tissues and 170
peritumoral tissues were included for immunohisto-
chemical analysis. All patients underwent a pretreatment
evaluation (e.g., basic personal information, a complete
history, a physical examination and a preoperative exam-
ination) and provided a complete follow-up data. The
data regarding the tumor (e.g., tumor location, differen-
tiation, T stage, N stage, distant metastasis) were
collected from the postoperative pathological results and
the preoperative examination. The tumor differentiation
grades were based on the World Health Organization
criteria, and the tumor-node-metastasis classificationswere defined according to the the American Joint Com-
mittee on Cancer (AJCC, 2009). The study was approved
by the Medical Ethics Committee of the Cancer Center
at Sun Yat-Sen University.
Follow-up data after surgery (e.g., recurrence, metasta-
sis, vital status, death and the causes of death) were
obtained from the patients’ records. All patients were
followed up every 4-6 months during the first 3 years
and every year thereafter. All patients’ vital statuses were
confirmed in January 2012.
Immunohistochemistry (IHC)
A total of 209 ESCC tissues and 170 paired peritumoral
normal esophageal tissues were fixed in 10% neutral
buffered formalin after complete surgical resection (R0)
Figure 1 (See legend on next page.)
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Figure 1 Immunohistochemical staining of esophageal squamous cell carcinoma (ESCC) and peritumoral normal esophageal mucosae
with anti-Cystatin SN. Low expression of Cystatin SN were detected in ESCC tissues (a, b and c, d), and the IRS grades of (a, b) and (c, d)
belong to absent(−) and weak(1+), respectively, in which (a, c) original magnification is × 100, and (b, d) original magnification is × 400,
respectively; High expression of Cystatin SN was detected in ESCC tissues (e, f and g, h) and peritumoral normal esophageal mucosae( i, j ), and
the IRS grades of (e, f) and (g, h and i, j) belong to moderate (2+) and strong (3+), respectively, in which (e, g, i) original magnification is × 100,
and (f, h, j) original magnification is × 400, respectively.
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and used for pathological evaluation. All paraffin-
embedded specimens used in this study were cut
into 4 μm sections and baked for 1 h at 65°C. IHC
staining was performed using the Dako Envision system
(Dako, Carpinteria, CA) following the manufacturer’s
recommended protocols, which have been described
previously [22]. Briefly, all sections were deparaffinised
and rehydrated and endogenous peroxidase activity was
blocked prior to immunostaining. Then, the slides were
processed for antigen retrieval by boiling in 10 mM cit-
rate buffer (pH 6.0) for 5 minutes. After natural cooling,
all sections were treated with a rabbit polyclonal
cystatin SN antibody (1:800 dilution; NBP1-55,995,
Novus, Littleton, USA) overnight at 4°C. Subsequently,
the sections were incubated with a biotinylated second-
ary antibody for 30 min at 37°C. Finally, the sections
were incubated with streptavidin-horseradish peroxid-
ase complex and developed with diaminobenzidine
(DAB). Mayer’s haematoxylin was used as a counter-
stain. For a negative control, the antibody was replaced
with normal rabbit serum.
IHC evaluation
The grading of the cytoplasmic Cystatin SN staining was
performed using light microscopy to generate an immu-
noreactivity score (IRS) [23,24]. The IRS of CST1 was
calculated by multiplying the intensity and extent scores.
Entire sections were observed to assign the scores. The
staining intensity was scored as 0 (no staining), 1 (weak
staining, yellow brown), 2 (moderate staining, yellow
brown), or 3 (strong staining, brown), and the percent-
age of positively stained cells was evaluated as 0 (0%), 1
(1% to 10%), 2 (11% to 50%), 3 (51% to 70%), or 4 (71%
to 100%). In our study, we used the median of all IRSsTable 2 Immunohistochemistry results for Cystatin SN in
esophageal squamous cell carcinoma (ESCC) compared
with peritumoral normal esophageal tissues
Cyatatin SN ESCC (N = 209) Peritumoral normal tissues (N = 170)
0 29 (13.9%) 0
1+ 116 (55.5%) 0
2+ 28 (13.4%) 0
3+ 36 (17.2%) 170 (100%)(4.0) as the cut-off point [25]. The IRS was classified
as: – (0 score, absent); 1+ (range from 1 to 4, weak); 2+
(range from 5 to 8 score, moderate); or 3+ (range from
9 to 12, strong). We defined – to 1+ as “Cystatin
SN- low expression” and 2+ to 3+ as “Cystatin SN- high
expression”.
The stained tissue sections were assessed and scored
independently by two senior pathologists (Ruo-Zhen
Luo and Jie-Hua He), both of whom were blinded to the
clinical characteristics of the patients. The final score for
Cystatin SN was defined using the average values of the
two observers’ scores. To ensure the consistency of the
scores, discordant cases were reviewed.
Statistical analysis
All statistical analyses were performed using the SPSS
13.0 statistical software package (SPSS, Chicago, IL). The
differences in the IRSs between ESCC and peritumoral
normal esophageal tissues were calculated using the
paired-sample Student test (paired-sample t-test). The
Chi-squared test (χ2 test) was used to analyse the corre-
lations between Cystatin SN expression and the clinico-
pathological characteristics of the ESCCs. Survival
curves were plotted using Kaplan-Meier plots and Log-
rank tests. Multivariate analysis was performed using the
Cox proportional hazard method, which was performed
for all significant variables using univariate analysis.
Overall survival (OS) and disease-free survival (DFS)
were calculated from the date of surgery to the date of
death or the last follow-up and to the date of recurrence




The clinicopathological characteristics of the 209 ESCC
patients are summarised in Table 1. Up to the last
follow-up visit (January 2012), the 1-, 3-, 5-, and 10-year
survival rates for the whole cohort of patients were
83.7%, 56.9%, 50.1% and 0.96%, respectively. None pa-
tients received neoadjuvant treatment. Excluding the pa-
tients who had KPS < 70 or/and refused chemotherapy,
79 patients have completed systemic adjuvant chemo-
therapy (cisplatin-based combinations) (OS, 66 months;
5-years survival, 53.8%) after curative-intent surgery.
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clinicopathological characteristics
Cystatin SN expression was observed predominantly in
the cytoplasm of the tumor cells and normal squamous
epithelial cells (Figure 1). Using the criteria described
above, strong staining (3+) of Cystatin SN was detected
in all of normal squamous epithelial cells, whereas vari-
ous staining patterns were obtained in the ESCC tissues.
There was a statistically significant difference between
the Cystatin SN staining of the tumors and the normal
tissues (P < 0.001, Table 2). However, there was no sig-
nificant associations between the Cystatin SN expression
of the ESCCs and age, gender, tumor location, differenti-
ation, T status, N status, and pathological stage in the
Chi-squared test (P > 0.05, Table 1).
Correlations between Cystatin SN expression, the patients
clinicopathological characteristics and survival
Up to the last follow-up date, 119 cancer-related ESCC
deaths were observed. The median observation period
was 56 months (range 3 to 134 months). The median
DFS and OS were 46 and 63 months, respectively.
In the Kaplan-Meier analysis, the expression of
cystatin SN was closely correlated with the DFS and OS
of ESCC patients. For the whole cohort, the median DFS
and OS were significantly longer for patients with high
tumoral expression levels of Cystatin SN than in patients
with low tumoural expression levels (both P < 0.001,
Figure 2, Table 3). Then, we examined the associations
between Cystatin SN expression and survival based on
the clinicopathological characteristics of the 209 ESCC
patients. The results showed that the expression levels
of Cystatin SN distinguished the patients with good DFSFigure 2 Kaplan-Meier survival of cystatin SN expression in esophage
(b) disease-free survival curves for the whole cohort of patients with ESCCand OS from patients with poor DFS and OS when the
patients were stratified by T status (pT1-2, P = 0.001 and
P = 0.001, respectively; pT3-4, P = 0.003 and P = 0.001,
respectively). This stratification based on the Cystatin
SN expression level was also observed for pN0 patients
(P < 0.001 and P < 0.001, respectively), stage II patients
(P < 0.001 and P < 0.001, respectively), tumor grade 1 pa-
tients (P = 0.003 and P = 0.001, respectively) and tumor
grade 2 patients (P = 0.001 and P = 0.002, respectively)
(Table 3).
A number of factors, including age, gender, tumor lo-
cation, surgery, differentiation, T status, N status and
cystatin SN expression, were used in the univariate Cox
regression analysis to assess their impact on the survival
of ESCC patients. The variables that were found to im-
pact survival in the univariate analysis were entered into
the multivariate analysis model. In this multivariate ana-
lysis model, the results showed that significant and inde-
pendent predictors of survival were the differentiation,
N status and Cystatin SN expression (Table 4).
Discussion
The CST1 gene, which encodes the S-type Cystatin SN
peptide, belongs to the Cystatin (CST) superfamily, the
members of which control the proteolytic activities of
cysteine proteases [5]. Studies have indicated that prote-
ases are involved in both primary and metastatic tumor
growth [26,27]. The CST1 gene is known to play a cru-
cial role in human gastrointestinal tract cancer, including
colon cancer and gastric cancer [6,27]. To the best of
our knowledge, our study is the first to systematically
evaluate the expression and clinicopathologic signifi-
cance of Cystatin SN in ESCC. Our findings haveal squamous cell carcinoma (ESCC) patients. (a) Overall survival and
( both P < 0.001).
Table 3 Prognostic value of Cystatin SN expression in 209 ESCC patients
Cystatin SN DFS (months) OS (months)
expression Cases Mean Median P-value* Mean Median P-value*
Total 209 < 0.001 < 0.001
Low expression 145 52 28 57 33
High expression 64 94 NR 100 NR
pT status 0.001 0.001
pT1-2 66
Low expression 43 56 29 60 35
High expression 23 108 NR 110 NR
pT3-4 143 0.003 0.001
Low expression 102 49 25 54 26
High expression 41 73 NR 80 NR
pN status
pN0 116 < 0.001 < 0.001
Low expression 76 70 67 75 72
High expression 40 118 NR 118 NR
PN1-3 93 0.058 0.017
Low expression 69 29 18 34 21
High expression 24 44 27 53 42
pTNM
Stage II 133 < 0.001 < 0.001
Low expression 88 67 56 72 67
High expression 45 117 NR 117 NR
Stage III 76 0.336 0.099
Low expression 57 27 11 31 19
High expression 19 34 26 45 40
Differentiation
G1 56 0.003 0.001
Low expression 39 67 66 71 67
High expression 17 106 NR 110 NR
G2 105 0.001 0.002
Low expression 68 49 28 54 35
High expression 37 92 NR 94 NR
G3 48 0.604 0328
Low expression 38 37 22 43 25
High expression 10 49 17 60 23
*Log-rank test.
DFS disease-free survival, OS overall survival, pT pathologic tumor, pN pathologic node, pTNM pathologic tumor-node-metastasis, G tumor grade, NR not reached.
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prognostic factor in ESCC patients.
In our study, the immunostaining of ESCC samples re-
vealed that Cystatin SN is predominantly located in the
cytoplasm. Previous studies showed that Cystatin SN
was present primarily in the cytosolic region of gastric
cancer cells, [6] but it was detected in the cytomem-
brane of colorectal cancer cells [21]. Those observationsindicate that the expression of Cystatin SN in different
cancers may be tissue–specific [9]. However, we failed to
show any significant correlations between Cystatin SN
expression and patients clinicopathological parameters.
In contrast, some studies revealed that overexpression of
Cystatin SN correlated with descending pathological
TNM stage for gastric and colorectal cancer. We believe
that can explained by the following factors. First, the
Table 4 Univariate and multivariate regression analysis for DFS and OS in the whole cohort
Variables
Disease-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI P value* HR 95% CI P value* HR 95% CI P value* HR 95% CI P value*
Age† 1.258 0.872-1.813 0.219 ..... ..... ..... 1.359 0.933-1.981 0.110 ..... ..... .....
Gender‡ 0.832 0.535-1.295 0.416 ..... ..... ..... 0.759 0.478-1.205 0.242 ..... ..... .....
Location§ 0.763 0.558-1.043 0.090 ..... ..... ..... 0.751 0.542-1.040 0.084 ..... ..... .....
Surgery¶ 1.034 0.851-1.256 0.738 ..... ..... ..... 1.052 0.863-1.284 0.615 ..... ..... .....
pT status¿ 1.133 0.782-1.644 0.509 ..... ..... ..... 1.118 0.772-1.618 0.554 ..... ..... .....
Differentiation£ 1.393 1.065-1.823 0.016 1.411 1.086-1.833 0.010 1.319 1.004-1.734 0.047 1.331 1.020-1.738 0.035
pN statusð 3.211 2.198-4.692 < 0.001 3.096 2.131-4.498 < 0.001 3.032 2.056-4.471 < 0.001 2.926 1.998-4.286 < 0.001
Cystatin SNζ 0.431 0.271-0.685 < 0.001 0.426 0.270-0.672 < 0.001 0.377 0.231-0.616 < 0.001 0.378 0.233-0.614 < 0.001
*Cox proportional hazards model; †Age ≤ 57 vs. Age > 57; ‡Male vs. Female; §Upper thoracic vs. Middle thoracic vs. Lower thoracic; ¶Left thoracotomy vs. Thoracic-
abdominal-cervical incision; ¿pT1 vs. pT2 vs. pT3 vs. pT4; £Tumor grade 1 vs. Tumor grade 2 vs. Tumor grade 3; ðpN0 vs. pN1/2/3; ζHigh expression of Cystatin SN
vs. low expression of Cystatin SN. HR hazard ratio, CI confidence interval, pT pathologic tumor, pN pathologic node.
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city. Second, the enrolled ESCCs is only II, III stages and
belongs to a single institution’s database, which may re-
sults in a selection bias and low statistical power to de-
tect meaningful relationships. Therefore, this concludion
merits additional research.
In the studies mentioned above, Cystatin SN, which
was proved to contribute to cell proliferation, has been
reported as an oncogene in colorectal and gastric
caicinoma [6,21]. Howere, in our study, we found that
ESCC patients with positive expression of Cystatin SN
had significantly longer DFS and OS than those with
negative Cystatin SN expression. We believe that can be
explained by two particular factors. Firstly, histology dif-
ferences such as squamous cell carcinoma and adenocar-
cinoma might explain the observed phenomena.
Secondly, the heterogeneity of biomarkers might also re-
sult in the discrepancies in the findings between the pre-
vious literatures and our study. These results are similar
to other members of the CST superfamily in a number
of previous reports. Cystatin C is a nonglycosylated
13 kDa basic protein, consisting of 120 amino acids. It
belongs to the cystatin superfamily of cysteine proteinase
inhibitors. Strojan et al [28] demonstrated significantly
longer survival in squamous cell carcinoma of the head
and neck patients with high Cystatin C than in those
with low Cystatin C. However, in colorectal cance [15],
the patients with high levels of Cystatin C exhibited a
significantly higher risk of death than those with lower
levels. Alterations in secretion may result in higher
extracellular and lower intracellular levels of Cystatin C
and, therefore, the reverse correlation of Cystatin C with
patients’ survival is to be expected. On the other hand,
one has to be aware that cysteine proteases and conse-
quently their inhibitors are also involved in biological
processes other than tissue remodeling during the pro-
gression of primary tumors, such as the regulation ofinflammatory and immune responses [29] or apoptosis
[30], so that different level of Cystatin C may lead to
various clinical outcomes. Moreover, in the subgroup
analysis, Cystatin SN expressions distinguish the DFS or
OS, especially in the groups of pN0 and stage II patients.
Our results suggested that Cystatin SN in ESCC maybe
play an significant role in the early stage of carcinogen-
esis. The underlying mechanism need further study.
The TNM stage is the most powerful and widely ac-
cepted predictor of survival for ESCCs [31]. However,
many patients with the same stage of disease have differ-
ent outcomes, indicating the TNM stage may be insuffi-
cient to distinguish ESCC patients’ survival [32]. An
increasing number of studies have focused on the use of
biomarkers to predict patients’ survival and select pa-
tients who will benefit from adjuvant treatments. To
date, the metastasis and invasiveness of several tumors
have been shown to be associated with members of the
CST superfamily, such as Cystatin C (encoded by CST3),
CystatinD (encoded by CST5), Cystatin F (encoded by
CST7), Cystatin M (encoded by CST6) and Cystatin S
(encoded by CST4), which have been described and in-
vestigated [11,13-18]. Our study focused on the relation-
ship between one of CST superfamily members and the
survival of cancer patients. In our study, Cystatin SN ex-
pression, combined with the N status and differentiation,
serve as independent and significant predictors in surgi-
cally resected ESCCs. Consistent with the findings
reported by the previous studies, we also suggested some
factors, including age, gender, tumor location, surgery
and pT status, were not the independently significant
predictive factors for ESCC survival, in spite of some
other different points. And some crowd confounding
factors may influence the foundings, of course, it needs
additional studies. On the other hand, the Cystatin SN
expression was shown to distinguish the DFS or OS in a
subgroup analysis, especially in the subgroups of pN0
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Cystatin SN expression combined with clinicopathologi-
cal parameters may serve as an extra factor for identify-
ing ESCC patients with a higher risk of tumor
recurrence and metastasis.
Unfortunately, one limitation of out study in the lack of
confirmation on Cystatin SN expression status by quanti-
tative methods like Reverse Transcription-Polymerase
Chain Reaction (RT-PCR), which could, in conjunction
with results of IHC, further refine the prognostic value of
this biomarker. Also, our study is a retrospective study, re-
lied exclusively on a single-institutional database. Add-
itional mechanistic investigations into this area will be
vital to facilitate our understanding of the biological sig-
nificance of Cystatin SN.
Conclusions
In conclusion, Cystatin SN expressed higher level in
peritumoral normal esophageal mucosae than in the
ESCC tissues. Compared with the patients with low ex-
pressive level of Cystatin SN, high expression patients
have more favourable survivals. Our findings have dem-
onstrated that Cystatin SN expression in ESCC tissue
may represent as an independent predictor of survival
for patients with resectable ESCC.
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